Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 0.68
TECH's Cash to Debt is ranked lower than
85% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. TECH: 0.68 )
Ranked among companies with meaningful Cash to Debt only.
TECH' s Cash to Debt Range Over the Past 10 Years
Min: 0.52  Med: 10000.00 Max: No Debt
Current: 0.68
Equity to Asset 0.76
TECH's Equity to Asset is ranked higher than
59% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. TECH: 0.76 )
Ranked among companies with meaningful Equity to Asset only.
TECH' s Equity to Asset Range Over the Past 10 Years
Min: 0.69  Med: 0.91 Max: 0.98
Current: 0.76
0.69
0.98
Interest Coverage 87.28
TECH's Interest Coverage is ranked lower than
66% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. TECH: 87.28 )
Ranked among companies with meaningful Interest Coverage only.
TECH' s Interest Coverage Range Over the Past 10 Years
Min: 95.22  Med: 10000.00 Max: 9999.99
Current: 87.28
95.22
9999.99
F-Score: 5
Z-Score: 10.03
M-Score: -2.56
WACC vs ROIC
6.63%
11.55%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 31.02
TECH's Operating margin (%) is ranked higher than
91% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. TECH: 31.02 )
Ranked among companies with meaningful Operating margin (%) only.
TECH' s Operating margin (%) Range Over the Past 10 Years
Min: 32.51  Med: 54.55 Max: 58.1
Current: 31.02
32.51
58.1
Net-margin (%) 21.32
TECH's Net-margin (%) is ranked higher than
88% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. TECH: 21.32 )
Ranked among companies with meaningful Net-margin (%) only.
TECH' s Net-margin (%) Range Over the Past 10 Years
Min: 23.82  Med: 37.16 Max: 40.8
Current: 21.32
23.82
40.8
ROE (%) 11.86
TECH's ROE (%) is ranked higher than
86% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. TECH: 11.86 )
Ranked among companies with meaningful ROE (%) only.
TECH' s ROE (%) Range Over the Past 10 Years
Min: 13.12  Med: 21.27 Max: 24.12
Current: 11.86
13.12
24.12
ROA (%) 8.94
TECH's ROA (%) is ranked higher than
88% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. TECH: 8.94 )
Ranked among companies with meaningful ROA (%) only.
TECH' s ROA (%) Range Over the Past 10 Years
Min: 11.19  Med: 20.19 Max: 22.16
Current: 8.94
11.19
22.16
ROC (Joel Greenblatt) (%) 62.50
TECH's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. TECH: 62.50 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TECH' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 71.74  Med: 109.84 Max: 114.76
Current: 62.5
71.74
114.76
Revenue Growth (3Y)(%) 12.60
TECH's Revenue Growth (3Y)(%) is ranked higher than
64% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. TECH: 12.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TECH' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 5.3  Med: 12.40 Max: 16.4
Current: 12.6
5.3
16.4
EBITDA Growth (3Y)(%) 2.40
TECH's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. TECH: 2.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TECH' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 1.5  Med: 13.00 Max: 41
Current: 2.4
1.5
41
EPS Growth (3Y)(%) -1.60
TECH's EPS Growth (3Y)(%) is ranked higher than
52% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. TECH: -1.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TECH' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.6  Med: 16.70 Max: 36.3
Current: -1.6
-1.6
36.3
» TECH's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

TECH Guru Trades in Q1 2015

Ray Dalio 4,282 sh (+7.53%)
Mairs and Power 1,379,687 sh (+6.50%)
Columbia Wanger 1,483,300 sh (unchged)
Ron Baron 1,053,220 sh (unchged)
Ruane Cunniff 2,540 sh (unchged)
Jeremy Grantham 27,100 sh (-4.58%)
Paul Tudor Jones 4,100 sh (-26.79%)
Chuck Royce 401,385 sh (-34.40%)
Jim Simons 281,100 sh (-46.63%)
» More
Q2 2015

TECH Guru Trades in Q2 2015

Chuck Royce 505,459 sh (+25.93%)
Ruane Cunniff 2,540 sh (unchged)
Ray Dalio Sold Out
Paul Tudor Jones Sold Out
Ron Baron 1,051,931 sh (-0.12%)
Mairs and Power 1,377,442 sh (-0.16%)
Columbia Wanger 1,436,847 sh (-3.13%)
Jim Simons 195,400 sh (-30.49%)
Jeremy Grantham 15,700 sh (-42.07%)
» More
Q3 2015

TECH Guru Trades in Q3 2015

George Soros 5,500 sh (New)
Ray Dalio 12,978 sh (New)
Chuck Royce 816,779 sh (+61.59%)
Ron Baron 1,400,394 sh (+33.13%)
Jim Simons 245,400 sh (+25.59%)
Ruane Cunniff 2,540 sh (unchged)
Jeremy Grantham Sold Out
Mairs and Power 1,293,524 sh (-6.09%)
Columbia Wanger 1,263,777 sh (-12.05%)
» More
Q4 2015

TECH Guru Trades in Q4 2015

Chuck Royce 908,569 sh (+11.24%)
Ron Baron 1,496,971 sh (+6.90%)
Mairs and Power 1,306,885 sh (+1.03%)
Ruane Cunniff 2,540 sh (unchged)
George Soros Sold Out
Columbia Wanger 847,288 sh (-32.96%)
Jim Simons 159,800 sh (-34.88%)
Ray Dalio 2,478 sh (-80.91%)
» More
» Details

Insider Trades

Latest Guru Trades with TECH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Bio-Techne Corp

Baron Funds Comments on Bio-Techne Corp - Nov 02, 2015

Bio-Techne Corporation (NASDAQ:TECH) sells specialized proteins, antibodies and other reagents, as well as instruments for protein analysis, to life sciences researchers at academic institutions, biopharmaceutical companies and government-funded research entities. Its products are used by scientists to investigate potential therapies for disease. Most of the company’s products are for research purposes only, and so they avoid the need for expensive, time-consuming regulatory approvals. The products are also relatively inexpensive, and they generally do not represent large cost items in most clients’ research budgets. With a portfolio of more than 275,000 products, Bio-Techne has by far the largest portfolio in its field, making the company a key supplier across its customer base.





We have also owned this stock in Baron Growth Fund for many years. We believe that Bio-Techne has attractive financial characteristics, including consistent revenue growth potential, high profit margins potential, and low capital requirements. We also believe the company has a reputation for manufacturing high quality, reliable, consistent products. The company has a staff of scientists who stay current with scientific advances and areas of interest for researchers and help direct product development into these growing areas.





Starting in 2010, the company’s organic growth slowed to the low single digits because of academic funding constraints, which hurt customer spending, and a lack of re-investments in the business by the former management team. Chuck Kummeth, who assumed the CEO position in April 2013, has been taking steps to reinvigorate growth, including hiring new executives and salespeople, making acquisitions, and expanding in China where the government is committed to investing in life sciences research.





We bought the stock in the quarter because we believe the fundamentals of this attractive business will continue to improve. In the most recently reported quarter, organic growth accelerated to 7%, the highest level in years. The funding environment for the company’s customer base is stable. Drug development budgets are improving. There have been proposed increases in the NIH budget, though uncertainty about the final budget remains. The company is annualizing the acquisition of a business called Protein Simple, which we believe has potential to drive revenue growth acceleration through the sale of its innovative instrument platform that automates the Western Blotting technique. Management has an aspirational plan to grow the company’s revenues to $1 billion in the next five years. Despite improving fundamentals, the stock price trades at what we believe is an attractive level.



From the Baron Asset Fund shareholder letter Q3 2015 by Andrew Peck.



Check out Ron Baron latest stock trades

Top Ranked Articles about Bio-Techne Corp

Mairs and Power Sells Baxalta, Walt Disney, Target Firm trims stake in Baxalta by 18%
Mairs & Power is an investment firm whose strength and success has resulted from applying a conservative growth investment approach consistently for over 70 years. The following are its largest sales during the third quarter. Read more...
Baron Funds Comments on Bio-Techne Corp Guru stock higlight
Bio-Techne Corporation (NASDAQ:TECH) sells specialized proteins, antibodies and other reagents, as well as instruments for protein analysis, to life sciences researchers at academic institutions, biopharmaceutical companies and government-funded research entities. Its products are used by scientists to investigate potential therapies for disease. Most of the company’s products are for research purposes only, and so they avoid the need for expensive, time-consuming regulatory approvals. The products are also relatively inexpensive, and they generally do not represent large cost items in most clients’ research budgets. With a portfolio of more than 275,000 products, Bio-Techne has by far the largest portfolio in its field, making the company a key supplier across its customer base. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 37.57
TECH's P/E(ttm) is ranked lower than
56% of the 239 Companies
in the Global Biotechnology industry.

( Industry Median: 30.00 vs. TECH: 37.57 )
Ranked among companies with meaningful P/E(ttm) only.
TECH' s P/E(ttm) Range Over the Past 10 Years
Min: 16.76  Med: 27.00 Max: 37.9
Current: 37.57
16.76
37.9
PE(NRI) 37.57
TECH's PE(NRI) is ranked lower than
55% of the 242 Companies
in the Global Biotechnology industry.

( Industry Median: 30.06 vs. TECH: 37.57 )
Ranked among companies with meaningful PE(NRI) only.
TECH' s PE(NRI) Range Over the Past 10 Years
Min: 16.78  Med: 27.03 Max: 37.85
Current: 37.57
16.78
37.85
Price/Owner Earnings (ttm) 30.80
TECH's Price/Owner Earnings (ttm) is ranked higher than
60% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 36.86 vs. TECH: 30.80 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
TECH' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 17.03  Med: 25.86 Max: 35.73
Current: 30.8
17.03
35.73
P/B 4.34
TECH's P/B is ranked lower than
58% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. TECH: 4.34 )
Ranked among companies with meaningful P/B only.
TECH' s P/B Range Over the Past 10 Years
Min: 3.27  Med: 4.63 Max: 8.27
Current: 4.34
3.27
8.27
P/S 8.01
TECH's P/S is ranked higher than
60% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. TECH: 8.01 )
Ranked among companies with meaningful P/S only.
TECH' s P/S Range Over the Past 10 Years
Min: 6.63  Med: 9.17 Max: 12.71
Current: 8.01
6.63
12.71
PFCF 32.28
TECH's PFCF is ranked higher than
52% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 30.80 vs. TECH: 32.28 )
Ranked among companies with meaningful PFCF only.
TECH' s PFCF Range Over the Past 10 Years
Min: 17.73  Med: 26.56 Max: 37.66
Current: 32.28
17.73
37.66
POCF 26.94
TECH's POCF is ranked lower than
51% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. TECH: 26.94 )
Ranked among companies with meaningful POCF only.
TECH' s POCF Range Over the Past 10 Years
Min: 15.79  Med: 23.64 Max: 31.69
Current: 26.94
15.79
31.69
EV-to-EBIT 25.84
TECH's EV-to-EBIT is ranked higher than
50% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.28 vs. TECH: 25.84 )
Ranked among companies with meaningful EV-to-EBIT only.
TECH' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.8  Med: 17.00 Max: 25.9
Current: 25.84
9.8
25.9
EV-to-EBITDA 20.27
TECH's EV-to-EBITDA is ranked higher than
54% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 20.97 vs. TECH: 20.27 )
Ranked among companies with meaningful EV-to-EBITDA only.
TECH' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.4  Med: 16.00 Max: 20.9
Current: 20.27
9.4
20.9
PEG 14.46
TECH's PEG is ranked lower than
87% of the 84 Companies
in the Global Biotechnology industry.

( Industry Median: 2.25 vs. TECH: 14.46 )
Ranked among companies with meaningful PEG only.
TECH' s PEG Range Over the Past 10 Years
Min: 1.01  Med: 2.21 Max: 15.52
Current: 14.46
1.01
15.52
Shiller P/E 33.79
TECH's Shiller P/E is ranked higher than
75% of the 51 Companies
in the Global Biotechnology industry.

( Industry Median: 54.60 vs. TECH: 33.79 )
Ranked among companies with meaningful Shiller P/E only.
TECH' s Shiller P/E Range Over the Past 10 Years
Min: 24.39  Med: 33.47 Max: 65.37
Current: 33.79
24.39
65.37
Current Ratio 7.21
TECH's Current Ratio is ranked higher than
66% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. TECH: 7.21 )
Ranked among companies with meaningful Current Ratio only.
TECH' s Current Ratio Range Over the Past 10 Years
Min: 3.27  Med: 9.66 Max: 21.99
Current: 7.21
3.27
21.99
Quick Ratio 5.57
TECH's Quick Ratio is ranked higher than
59% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. TECH: 5.57 )
Ranked among companies with meaningful Quick Ratio only.
TECH' s Quick Ratio Range Over the Past 10 Years
Min: 2.82  Med: 8.99 Max: 21.04
Current: 5.57
2.82
21.04
Days Inventory 132.22
TECH's Days Inventory is ranked lower than
53% of the 441 Companies
in the Global Biotechnology industry.

( Industry Median: 121.91 vs. TECH: 132.22 )
Ranked among companies with meaningful Days Inventory only.
TECH' s Days Inventory Range Over the Past 10 Years
Min: 63.05  Med: 97.56 Max: 192.76
Current: 132.22
63.05
192.76
Days Sales Outstanding 51.90
TECH's Days Sales Outstanding is ranked higher than
61% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. TECH: 51.90 )
Ranked among companies with meaningful Days Sales Outstanding only.
TECH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.81  Med: 44.94 Max: 56.52
Current: 51.9
40.81
56.52
Days Payable 25.43
TECH's Days Payable is ranked lower than
75% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 64.47 vs. TECH: 25.43 )
Ranked among companies with meaningful Days Payable only.
TECH' s Days Payable Range Over the Past 10 Years
Min: 28.64  Med: 33.49 Max: 54.23
Current: 25.43
28.64
54.23

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.29
TECH's Dividend Yield is ranked higher than
56% of the 206 Companies
in the Global Biotechnology industry.

( Industry Median: 1.33 vs. TECH: 1.29 )
Ranked among companies with meaningful Dividend Yield only.
TECH' s Dividend Yield Range Over the Past 10 Years
Min: 0.39  Med: 1.48 Max: 1.82
Current: 1.29
0.39
1.82
Dividend Payout 0.48
TECH's Dividend Payout is ranked lower than
73% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 0.33 vs. TECH: 0.48 )
Ranked among companies with meaningful Dividend Payout only.
TECH' s Dividend Payout Range Over the Past 10 Years
Min: 0.3  Med: 0.38 Max: 0.53
Current: 0.48
0.3
0.53
Dividend Growth (3y) 4.60
TECH's Dividend Growth (3y) is ranked lower than
52% of the 89 Companies
in the Global Biotechnology industry.

( Industry Median: 5.60 vs. TECH: 4.60 )
Ranked among companies with meaningful Dividend Growth (3y) only.
TECH' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 14
Current: 4.6
0
14
Forward Dividend Yield 1.27
TECH's Forward Dividend Yield is ranked higher than
54% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 1.33 vs. TECH: 1.27 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.61
TECH's Yield on cost (5-Year) is ranked higher than
56% of the 254 Companies
in the Global Biotechnology industry.

( Industry Median: 1.55 vs. TECH: 1.61 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TECH' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.49  Med: 1.84 Max: 2.27
Current: 1.61
0.49
2.27
3-Year Average Share Buyback Ratio -0.20
TECH's 3-Year Average Share Buyback Ratio is ranked higher than
90% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.70 vs. TECH: -0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TECH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.9  Med: 0.80 Max: 2
Current: -0.2
-2.9
2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 31.80
TECH's Price/Tangible Book is ranked lower than
93% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. TECH: 31.80 )
Ranked among companies with meaningful Price/Tangible Book only.
TECH' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.13  Med: 6.19 Max: 40.34
Current: 31.8
4.13
40.34
Price/Projected FCF 1.80
TECH's Price/Projected FCF is ranked higher than
75% of the 176 Companies
in the Global Biotechnology industry.

( Industry Median: 3.66 vs. TECH: 1.80 )
Ranked among companies with meaningful Price/Projected FCF only.
TECH' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.27  Med: 2.03 Max: 12.77
Current: 1.8
1.27
12.77
Price/DCF (Earnings Based) 3.34
TECH's Price/DCF (Earnings Based) is ranked lower than
83% of the 18 Companies
in the Global Biotechnology industry.

( Industry Median: 1.15 vs. TECH: 3.34 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.88
TECH's Price/Median PS Value is ranked higher than
61% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. TECH: 0.88 )
Ranked among companies with meaningful Price/Median PS Value only.
TECH' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.4  Med: 1.00 Max: 2.85
Current: 0.88
0.4
2.85
Price/Graham Number 7.28
TECH's Price/Graham Number is ranked lower than
84% of the 293 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. TECH: 7.28 )
Ranked among companies with meaningful Price/Graham Number only.
TECH' s Price/Graham Number Range Over the Past 10 Years
Min: 1.97  Med: 2.78 Max: 10.85
Current: 7.28
1.97
10.85
Earnings Yield (Greenblatt) (%) 3.90
TECH's Earnings Yield (Greenblatt) (%) is ranked higher than
86% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. TECH: 3.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TECH' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.9  Med: 5.90 Max: 10.2
Current: 3.9
3.9
10.2
Forward Rate of Return (Yacktman) (%) 5.59
TECH's Forward Rate of Return (Yacktman) (%) is ranked lower than
64% of the 108 Companies
in the Global Biotechnology industry.

( Industry Median: 13.93 vs. TECH: 5.59 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TECH' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 5.6  Med: 14.90 Max: 25.7
Current: 5.59
5.6
25.7

More Statistics

Revenue(Mil) $465
EPS $ 2.66
Beta0.64
Short Percentage of Float5.21%
52-Week Range $79.95 - 114.56
Shares Outstanding(Mil)37.19

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:RO, OCSE:NOVO B, NAS:GILD, NAS:AMGN, NAS:CELG, NAS:BIIB » details
Traded in other countries:TE1.Germany,
Bio-Techne Corp was founded as Research and Diagnostic Systems, Inc. (R&D Systems) in 1976. In November 2014, the company's name was changed from Techne Corporation to Bio-Techne Corporation. The Company and its subsidiaries develops, manufactures and sells biotechnology reagents, instruments and clinical diagnostic products. The Company's business segments are the Biotechnology, Clinical Controls and Protein Platforms divisions. The Biotechnology segment supply's the proteins, such as cytokines, growth factors, immunoassays, antibodies and related reagents, to the biotechnology research community. It isolates and produces proteins in a pure form either from the native cells or through recombinant DNA technology. The Clinical Controls segment develops and manufactures controls and calibrators for instruments in the global clinical market. The Company offers a wide range of hematology controls and calibrators for both impedance and laser type cell counters. It also supply's hematology control products for use as proficiency testing tools by laboratory certifying authorities in a number of states and countries. The Protein Platforms segment develops, manufactures and sells tools to make protein analysis simpler, more quantitative and reproduceable. The Company sells its protein platforms products directly to customers located in North America, western Europe and Japan. It also sells through third party distributors in China, southern Europe and the rest of the world. The Company's competitors include GE Healthcare Life Sciences, BD Biosciences, Merck KGaA/EMD Chemicals, Inc., PeproTech, Inc., Santa Cruz Biotechnology, Inc., Abcam plc., Thermo Fisher Scientific, Inc., Cayman Chemical Company and Enzo Biochem, Inc, Abbott Diagnostics, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Streck, Inc., Siemens Healthcare Diagnostics Inc. and Sysmex Corporation, Bio-Rad Laboratories, GE Healthcare, Merck KGaA, PerkinElmer and Thermo Fisher Scientific. It operates in United States, Europe, China, Other Asia and Rest of world. The Company is subject to the medical device excise tax which was included as part of the Affordable Care Act.
» More Articles for TECH

Headlines

Articles On GuruFocus.com
Mairs and Power Sells Baxalta, Walt Disney, Target Dec 16 2015 
Baron Funds Comments on Bio-Techne Corp Nov 02 2015 
Two Biotech Stocks to Buy, One to Avoid Jan 09 2012 
Chuck Akre MA, AMT, ESGR, ROST, TECH, KMB; Sells WRB, CRI, GLRE, RP, XOM Feb 13 2011 
Techne Corp. Reports Operating Results (10-Q) Feb 09 2011 
Techne Corp. Reports Operating Results (10-Q) Nov 09 2010 
Techne Corp. Reports Operating Results (10-K) Aug 27 2010 
Chuck Royce’s Top Predictable Companies: MEDNAX, Techne Corp., ITT Educational Services, Exactech May 17 2010 
Techne Corp. Reports Operating Results (10-Q) May 07 2010 
Techne Corp. Reports Operating Results (10-Q) Feb 08 2010 

More From Other Websites
Bio-Techne Corporation Acquires Access to B-MoGen Biotechnologies’ Gene Editing Technology May 04 2016
Bio-Techne Gets Access To B-MoGen Biotechnologies' Gene Editing Technology May 04 2016
Bio-Techne Corporation Acquires Access to B-MoGen Biotechnologies' Gene Editing Technology May 04 2016
Edited Transcript of TECH earnings conference call or presentation 3-May-16 1:00pm GMT May 03 2016
Bio-Techne Releases Third Quarter Fiscal Results May 03 2016
Bio-Techne Declares Dividend May 03 2016
Q3 2016 Bio-Techne Corp Earnings Release - Before Market Open May 03 2016
7:06 am Bio-Techne beats by $0.12, beats on revs May 03 2016
BIO-TECHNE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... May 03 2016
Bio-Techne Declares Dividend May 03 2016
Bio-Techne Releases Third Quarter Fiscal 2016 Results May 03 2016
Bio-Techne To Host Conference Call On May 3, 2016 To Announce Third Quarter Financial Results Apr 11 2016
Zacks Investment Ideas feature highlights: Tech Data, Johnson Outdoor, Central Garden and Delta... Mar 24 2016
[$$] Bio-Techne Acquires Zephyrus Biosciences Mar 22 2016
Bio-Techne Buys Zephyrus, Boosts Protein Platforms Division Mar 22 2016
Bio-Techne Corporation Agrees to Acquire Zephyrus Biosciences, Inc. Mar 21 2016
Bio-Techne Corporation Agrees to Acquire Zephyrus Biosciences, Inc. Mar 21 2016
Bio-Techne Corp. breached its 50 day moving average in a Bearish Manner : TECH-US : March 1, 2016 Mar 01 2016
Equity Market Performance at Large - Free Research Reports on Legg Mason, Booz Allen Hamilton... Mar 01 2016
BIO-TECHNE CORP Financials Feb 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK